Literature DB >> 2418898

Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production.

G J Dover, R K Humphries, J G Moore, T J Ley, N S Young, S Charache, A W Nienhuis.   

Abstract

Initial alterations in fetal hemoglobin (HbF) production among eight sickle cell anemia subjects treated with hydroxyurea (Hu) are summarized. Four of these subjects had been previously treated with 5-azacytidine (5-aza). All subjects treated with Hu (50 mg/kg/d for three to five days) had suppression of their total reticulocyte counts by seven days, whereas the four subjects previously treated with 5-aza (2 mg/kg/d for three to five days) had increased reticulocyte counts at day 7. The effect of Hu on increasing the number of HbF-containing reticulocytes (F reticulocytes) is extremely variable, ranging from ten-to less than onefold differences in maximal posttherapy v pretherapy levels. Recovery from marrow suppression did not result in greater than twofold increases in F reticulocyte counts. Mean day 7 F reticulocyte levels in the four subjects treated with both Hu and 5-aza were 4.1 X 10/microL and 15.4 X 10(4)/microL, respectively. Among Hu-treated subjects, increased F reticulocyte production was correlated with low serum creatinine levels and rapid removal of Hu from the plasma. Furthermore, suppression of CFU-E colony formation on day 2 of therapy with Hu was inversely correlated with maximal F reticulocyte response. We conclude that where Hu treatment results in marrow toxicity (decreased reticulocyte counts, decreased CFU-E colony formation) HbF production is less likely to increase. Those sickle cell anemia subjects with minimal renal dysfunction (serum creatinine level, greater than 1.0 mg/dL) exhibit the most cytotoxicity and least F reticulocyte response to Hu.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418898

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Reticulocytes and reticulocyte enumeration.

Authors:  R S Riley; J M Ben-Ezra; R Goel; A Tidwell
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Comparison of radial immunodiffusion and alkaline cellulose acetate electrophoresis for quantitating elevated levels of fetal hemoglobin (HbF): application to evaluating patients with sickle cell disease treated with hydroxyurea.

Authors:  J C Schultz
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 3.  Hydroxyurea for children with sickle cell disease.

Authors:  Matthew M Heeney; Russell E Ware
Journal:  Hematol Oncol Clin North Am       Date:  2010-02       Impact factor: 3.722

Review 4.  Pharmacological modification of hemoglobin F expression in sickle cell anemia: an update on hydroxyurea studies.

Authors:  S Charache
Journal:  Experientia       Date:  1993-02-15

5.  The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Authors:  Shuaiying Cui; Kim-Chew Lim; Lihong Shi; Mary Lee; Natee Jearawiriyapaisarn; Greggory Myers; Andrew Campbell; David Harro; Shigeki Iwase; Raymond C Trievel; Angela Rivers; Joseph DeSimone; Donald Lavelle; Yogen Saunthararajah; James Douglas Engel
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

6.  Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience.

Authors:  E Papadopoulou; A Teli; S Theodoridou; N Gompakis; M Economou
Journal:  Hippokratia       Date:  2015 Apr-Jun       Impact factor: 0.471

Review 7.  Pharmacokinetics and pharmacodynamics of hydroxyurea.

Authors:  P R Gwilt; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 8.  Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies.

Authors:  S P Perrine; D V Faller
Journal:  Experientia       Date:  1993-02-15

Review 9.  Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.

Authors:  Min Dong; Patrick T McGann
Journal:  Clin Pharmacol Ther       Date:  2020-10-08       Impact factor: 6.875

10.  Population pharmacokinetics of hydroxyurea in cancer patients.

Authors:  W G Tracewell; D L Trump; W P Vaughan; D C Smith; P R Gwilt
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.